323 Treatment With Chondroitin Sulfate Reduces Cartilage Volume Loss in Knee Oa Patients Assessed by Mri: A Randomized, Double-Blind, Placebo Controlled Pilot Study

A Road Map to Commercialization of Cartilage Therapy in the United States of America

“…85 Condrosan is a hard capsule of chondroitin sulfate marketed by Bioiberica in Canada and Spain. Publication and clinical studies revealed that Condrosan was found to perform better than Celecoxib, an anti-inflammatory, steroidbased painkiller drug, 83,86 and reduced cartilage volume loss and marrow lesions in the knee as early as 6 months after administration. 86 Condrosan represents a symptomatic treatment, and future long-term analysis (phase IV) will help to determine efficiency of pain relief for arthritic patients.…”